EMA accepts Dynavax's MAA for Heplisav
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has accepted the marketing authorisation application (MAA) for Dynavax Technologies' hepatitis B vaccine, Heplisav, an immunostimulatory sequence targeting toll-like receptor 9 combined with hepatitis B surface antigen.